| Literature DB >> 35163913 |
Fatimah Y Alomari1, Abeer A Sharfalddin2, Magda H Abdellattif3, Doaa Domyati4, Amal S Basaleh2, Mostafa A Hussien2,5.
Abstract
Four new drug-based oxidovanadium (IV) complexes were synthesized and characterized by various spectral techniques, including molar conductance, magnetic measurements, and thermogravimetric analysis. Moreover, optimal structures geometry for all syntheses was obtained by the Gaussian09 program via the DFT/B3LYP method and showed that all of the metal complexes adopted a square-pyramidal structure. The essential parameters, electrophilicity (ω) value and expression for the maximum charge that an electrophile molecule may accept (ΔNmax) showed the practical biological potency of [VO(CTZ)2] 2H2O. The complexes were also evaluated for their propensity to bind to DNA through UV-vis absorption titration. The result revealed a high binding ability of the [VO(CTZ)2] 2H2O complex with Kb = 1.40 × 10⁶ M-1. Furthermore, molecular docking was carried out to study the behavior of the VO (II) complexes towards colon cancer cell (3IG7) protein. A quantitative structure-activity relationship (QSAR) study was also implemented for the newly synthesized compounds. The results of validation indicate that the generated QSAR model possessed a high predictive power (R2 = 0.97). Within the investigated series, the [VO(CTZ)2] 2H2O complex showed the greatest potential the most selective compound comparing to the stander chemotherapy drug.Entities:
Keywords: DFT modeling; DNA binding; QSAR study; docking; oxidovanadium(IV) complexes
Mesh:
Substances:
Year: 2022 PMID: 35163913 PMCID: PMC8838224 DOI: 10.3390/molecules27030649
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
The effective analytical and physical data of ligands and their oxidovanadium (IV) complexes.
| Complex | M.wt. (g mol−1) | Color | M.P. | % Found (calc.) | Λm | ||
|---|---|---|---|---|---|---|---|
| C | H | N | |||||
| CBZ | 185.2 | White | 113 | 45.15 | 5.41 | 15.04 | 1 |
| [VO(SO4)(CBZ)] 8H2O | 493.3 | Green | 125 | 17.04 | 5.31 | 5.68 | 7.47 |
| CTZ | 461.8 | White | 140 | 54.62 | 5.89 | 6.07 | 5.23 |
| [VO(CTZ)2] 2H2O | 878.7 | Heavy blue | 134 | 57.41 | 5.96 | 6.38 | 8.85 |
| LOR | 371.8 | Yellow | 225 | 42.00 | 2.71 | 11.30 | 4.00 |
| [VO(LOR)2] SO4 | 906.6 | Brown | 124 | 35.71 | 2.31 | 9.61 | 68.85 |
| SCZ | 250.1 | White | 130 | 42.19 | 3.19 | 19.68 | 1.3 |
| [VO(SO4)(SCZ)] 7H2O | 573.8 | Green | 209 | 20.93 | 4.04 | 9.76 | 17.50 |
Figure 1The suggested structures for oxidovanadium(IV) complexes.
Figure 2A comparison of the IR spectra of free CTZ ligand and its oxidovanadium(IV) complex in the range 4000–500 cm−1.
The main bands in IR spectra in the range 4000–500 cm−1 for ligands and their oxidovanadium(IV) complexes.
| Compound | ν(C=O) | ν(C=N) | ν(C=S) | ν(S=O) | ν(V-O) | ν(V-N) | ν(V-S) | νasym, νsym (SO4) |
|---|---|---|---|---|---|---|---|---|
| CBZ | 1677 | - | 1271 | - | - | - | - | - |
| VO(SO4)(CBZ)] 8H2O | 1677 | - | 1279 | - | 596 | 422 | - | 1310–1035 |
| CTZ | 1739 | - | - | - | - | - | - | - |
| [VO(CTZ)2] 2H2O | 1599, 1409 | - | - | - | 544 | - | ||
| LOR | 1647 | 1591 | - | - | - | - | - | |
| [VO(LOR)2] SO4 | 1668 | 1621 | - | - | 521 | 496 | ||
| SCZ | - | 1670 | - | 1271 | - | - | - | |
| [VO(SO4)(SCZ)] 7H2O | - | 1671 | - | 1033 | 589 | - | 424 | 1280–1011 |
Figure 3Electronic absorption spectrum of free CTZ ligand and its metal complex (inset shows the d-d transition the metal complex).
Electronic spectra data of ligand and their oxidovanadium(IV) complexes and their magnetic moment values.
| Compound | π–π* | n–π* | µeff. | d-d (broad) |
|---|---|---|---|---|
| CBZ | 266 | - | - | |
| [VO(SO4)(CBZ)] 8H2O | 273 | - | 1.74 | 850 |
| CTZ | 262 | 280 | - | |
| [VO(CTZ)2] 2H2O | 260 | 331 | 1.75 | 900 |
| LOR | 274 | 394 | - | |
| [VO(LOR)2] SO4 | 263 | 311 | 1.76 | 850 |
| SCZ | 262 | 275 | - | |
| [VO(SO4)(SCZ)] 7H2O | 282 | 373 | 1.75 | 870 |
EPR parameter in DMF at room temperature of oxidovanadium(IV) complexes.
| Complex | g | A |
|---|---|---|
| [VO(SO4)(CBZ)] 8H2O | 1.992 | 96 |
| [VO(CTZ)2] 2H2O | 1.980 | 106 |
| [VO(LOR)2] SO4 | 1.982 | 105 |
| [VO(SO4)(SCZ)] 7H2O | 1.984 | 108 |
Figure 4EPR spectrum of [VO(CTZ)2] 2H2O in DMF at room temperature.
Figure 5The TGA curve decomposition in the range 25–800 °C of [VO(CTZ)2] 2H2O complex.
The optimized geometry and V=O bond length of the metal complexes in the gas phase using DFT method LANL2DZ basis sets.
| Compound | Optimized Geometry |
| [VO(SO4)(CBZ)] 8H2O |
|
| [VO(CTZ)2] 2H2O |
|
| [VO(LOR)2]SO4 |
|
| [VO(SO4)(SCZ)] 7H2O |
|
Bond lengths and stretching frequencies for V=O Bonds in synthesized oxidovanadium(IV) complexes, experimental, and theoretical values.
| Complex | ν(V=O) | V=O Radius | ||
|---|---|---|---|---|
| Exp | DFT | Exp | DFT | |
| [VO(SO4)(CBZ)] 8H2O | 980 | 1037 | 1.607 | 1.599 |
| [VO(CTZ)2] 2H2O | 963 | 1068 | 1.616 | 1.579 |
| [VO(LOR)2]SO4 | 968 | 1075 | 1.613 | 1.576 |
| [VO(SO4)(SCZ)] 7H2O | 987 | 1047 | 1.603 | 1.596 |
EHOMO, ELUMO, Eg, and the ligand’s quantum parameters and complexes using B3LYP/LANL2DZ.
| Compound | HUMO | LUMO | ∆E | x | η | σ | Pi | σ | S | ω | ΔN Max |
|---|---|---|---|---|---|---|---|---|---|---|---|
| CBZ | −5.55 | −1.00 | 4.55 | 3.28 | 2.28 | 0.44 | −3.28 | 0.44 | 1.14 | 2.36 | 1.44 |
| VO-CBZ | −7.09 | −3.27 | 3.83 | 5.18 | 1.91 | 0.52 | −5.18 | 0.96 | 0.96 | 2.59 | 2.71 |
| SCZ | −6.75 | −2.78 | 3.97 | 4.77 | 1.99 | 0.50 | −4.77 | 0.99 | 0.99 | 2.38 | 2.40 |
| VO-SCZ | −7.41 | −3.64 | 3.77 | 5.53 | 1.89 | 0.53 | −5.53 | 0.94 | 0.94 | 2.76 | 2.93 |
| LOR | −3.96 | −1.99 | 1.97 | 2.98 | 0.98 | 1.02 | −2.98 | 0.49 | 0.49 | 1.49 | 3.03 |
| VO-LOR | −3.93 | −2.74 | 1.19 | 3.34 | 0.59 | 1.68 | −3.34 | 0.30 | 0.30 | 1.67 | 5.62 |
| CTZ | −6.59 | −4.68 | 1.91 | 5.64 | 0.95 | 1.05 | −5.64 | 0.48 | 0.48 | 2.82 | 5.91 |
| VO-CTZ | −10.26 | −8.84 | 1.42 | 10.05 | 1.21 | 0.83 | −10.05 | 0.61 | 0.61 | 5.03 | 8.31 |
The spectral parameters for the interaction of oxidovanadium(IV) complexes and their ligands with DNA.
| Compound | Kb (M−1) | λmax Free (nm) | λmax Bound (nm) | Type of Chromism |
|---|---|---|---|---|
| CBZ | 8.33 × 105 | 261 | 255 | Hyperchromic |
| [VO(SO4)(CBZ)] 8H2O | 5.00 × 105 | 265 | 256 | Hyperchromic |
| CTZ | 1.00 × 106 | 263 | 263 | Hyperchromic |
| [VO(CTZ)2] 2H2O | 1.40 × 106 | 265 | 259 | Hyperchromic |
| LOR | 8.33 × 105 | 395 | 376 | Hypochromic |
| [VO(LOR)2] SO4 | 1.20 × 106 | 281 | 274 | Hyperchromic |
| SCZ | 1.00 × 106 | 265 | 257 | Hyperchromic |
| [VO(SO4)(SCZ)] 7H2O | 1.25 × 106 | 262 | 256 | Hyperchromic |
Figure 6Absorption spectra of CTZ and its metal complex in the presence of increasing DNA concentration (arrow indicates changes with increasing DNA concentration).
Docking score and energies of ligands and their oxidovanadium(IV) complexes with 3IG7 protein.
| Compound | S | rmsd_Refine | E_conf | E_Place | E_Refine |
|---|---|---|---|---|---|
| CBZ | −5.13 | 0.95 | −16.39 | −50.34 | −27.37 |
| [VO(SO4)(CBZ)] 8H2O | −5.95 | 2.88 | −624.55 | −49.81 | −15.08 |
| CTZ | −7.60 | 1.41 | 129.88 | −92.44 | −28.38 |
| [VO(CTZ)2] 2H2O | −9.81 | 1.86 | −658.30 | −79.50 | −29.23 |
| LOR | −6.58 | 1.04 | 2.82 | −87.23 | −36.53 |
| [VO(LOR)2] SO4 | −6.83 | 2.35 | −358.53 | −1.13 | −37.58 |
| SCZ | −5.83 | 1.93 | −40.53 | −57.04 | −31.67 |
| [VO(SO4)(SCZ)] 7H2O | −6.90 | 1.16 | −797.18 | −79.19 | −9.94 |
2D and 3D Docking interaction of the oxidovanadium(IV) complexes with colon cancer protein (PDB code = 3IG7).
| Compound | 2D Snapshot | 3D Snapshot |
|---|---|---|
| CBZ |
|
|
| [VO(SO4)(CBZ)] 8H2O |
|
|
| CTZ |
|
|
| [VO(CTZ)2] 2H2O |
|
|
| LOR |
|
|
| [VO(LOR)2]SO4 |
|
|
| SCZ |
|
|
| [VO(SO4)(SCZ)] 7H2O |
|
|
|
| ||
Figure 7MLR correlation between Predicted anticancer activities of “IC50” and experimental values of training set.
The predicted IC50 of all synthesized oxidovanadium(IV) complexes and their free ligands (testing set) against HCT116 cell.
| Compound | Predicted IC50 (µM) |
|---|---|
| CBZ | 42.43 |
| [VO(SO4)(CBZ)] 8H2O | 39.87 |
| CTZ | 12.30 |
| [VO(CTZ)2] 2H2O | 1.45 |
| LOR | 10.26 |
| [VO(LOR)2] SO4 | 2.61 |
| SCZ | 17.62 |
| [VO(SO4)(SCZ)] H2O | 37.06 |
Anticancer activity of [VO(CTZ)2] 2H2O compared to Cisplatin and the stander division value.
| Complex | IC50 ± SD (µM) |
|---|---|
| [VO(CTZ)2] 2H2O | 2.11 ± 0.02 |
| Cisplatin | 2.13 0.03 |